Hong Sang

Array ( [id] => 18666303 [patent_doc_number] => 11773181 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Anti-survivin antibodies for cancer therapy [patent_app_type] => utility [patent_app_number] => 16/990622 [patent_app_country] => US [patent_app_date] => 2020-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 10255 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 198 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16990622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657457 [patent_doc_number] => 20210054093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => Novel CD47 Monoclonal Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/989702 [patent_app_country] => US [patent_app_date] => 2020-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14930 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 352 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18887725 [patent_doc_number] => 11866487 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Filamin A binding proteins and uses thereof [patent_app_type] => utility [patent_app_number] => 16/935596 [patent_app_country] => US [patent_app_date] => 2020-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 39450 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 382 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16935596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16613674 [patent_doc_number] => 20210032327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/934143 [patent_app_country] => US [patent_app_date] => 2020-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16934143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17053598 [patent_doc_number] => 20210263032 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => LIQUID BIOPSY YIELD ENHANCEMENT [patent_app_type] => utility [patent_app_number] => 16/932989 [patent_app_country] => US [patent_app_date] => 2020-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16932989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16398844 [patent_doc_number] => 20200339702 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => DE-IMMUNISED ANTI-ERBB3 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/925570 [patent_app_country] => US [patent_app_date] => 2020-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24556 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16925570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18871201 [patent_doc_number] => 11858988 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-02 [patent_title] => Antibodies specific for claudin 6 (CLDN6) [patent_app_type] => utility [patent_app_number] => 16/922179 [patent_app_country] => US [patent_app_date] => 2020-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 31 [patent_no_of_words] => 40119 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 567 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16922179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590561 [patent_doc_number] => 10899811 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => B*44 restricted peptides for use in immunotherapy against cancers and related methods [patent_app_type] => utility [patent_app_number] => 16/916450 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 41 [patent_no_of_words] => 42203 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16916450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590560 [patent_doc_number] => 10899810 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => B*44 restricted peptides for use in immunotherapy against cancers and related methods [patent_app_type] => utility [patent_app_number] => 16/916447 [patent_app_country] => US [patent_app_date] => 2020-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 41 [patent_no_of_words] => 41939 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16916447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16696732 [patent_doc_number] => 10947313 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Anti-EphA4 antibody [patent_app_type] => utility [patent_app_number] => 16/915412 [patent_app_country] => US [patent_app_date] => 2020-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 24 [patent_no_of_words] => 19353 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16915412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16375125 [patent_doc_number] => 20200323967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/915283 [patent_app_country] => US [patent_app_date] => 2020-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33187 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16915283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16359431 [patent_doc_number] => 20200316182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/910937 [patent_app_country] => US [patent_app_date] => 2020-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16910937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621581 [patent_doc_number] => 20210040234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => Enhancing Activity of CAR T Cells by Co-Introducing a Bispecific Antibody [patent_app_type] => utility [patent_app_number] => 16/910837 [patent_app_country] => US [patent_app_date] => 2020-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16910837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570699 [patent_doc_number] => 20210009705 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => ANTI-OX40 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/911229 [patent_app_country] => US [patent_app_date] => 2020-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 76642 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16911229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16689769 [patent_doc_number] => 20210072246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => BIOMARKERS FOR DETECTION OF OVARIAN CANCER [patent_app_type] => utility [patent_app_number] => 16/895943 [patent_app_country] => US [patent_app_date] => 2020-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7978 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16895943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16341724 [patent_doc_number] => 20200306374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/895239 [patent_app_country] => US [patent_app_date] => 2020-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16895239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19940280 [patent_doc_number] => 12312402 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-27 [patent_title] => Antibody or chimeric antigen receptor which targets Claudin 18.2 [patent_app_type] => utility [patent_app_number] => 17/601765 [patent_app_country] => US [patent_app_date] => 2020-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 29 [patent_no_of_words] => 6391 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 208 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17601765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16482431 [patent_doc_number] => 20200376031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => VIRAL VECTORS AND USE THEREOF IN ADOPTIVE CELLULAR THERAPY [patent_app_type] => utility [patent_app_number] => 16/884804 [patent_app_country] => US [patent_app_date] => 2020-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22146 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16884804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16468230 [patent_doc_number] => 20200369767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => REGIMES FOR CO-ADMINISTRATION OF IMMUNOTHERAPEUTIC AGENTS AGAINST C-KIT AND CD47 [patent_app_type] => utility [patent_app_number] => 16/880661 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18418 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16880661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720494 [patent_doc_number] => 20220213214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => Anti-human ephrin B1 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/606847 [patent_app_country] => US [patent_app_date] => 2020-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17606847 [rel_patent_id] =>[rel_patent_doc_number] =>)